Form 4: Precigen CEO Sells Shares Under 10b5-1 Plan

Precigen, Inc. (PGEN) President and CEO Helen Sabzevari sold 346,836 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Helen Sabzevari, President and CEO of Precigen, Inc., reported a transaction on June 29, 2026.
• She sold 346,836 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan, which is designed to satisfy affirmative defense conditions for insider trading.
• The average sale price was $5.89 per share, with individual sales ranging from $5.75 to $6.04.
• Following this transaction, Sabzevari beneficially owns 3,768,872 shares of common stock.
• Additionally, the filing notes that 346,836 stock options, with an exercise price of $2.33, are fully vested and held by Sabzevari.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a significant sale by the CEO can be concerning, the execution under a 10b5-1 plan mitigates concerns about insider trading and the CEO retains substantial ownership.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-knowledge-based trading.
• The CEO still beneficially owns a significant number of shares (3,768,872) after the sale.
• The stock options held are fully vested, suggesting potential future value realization.

Negatives

• A significant number of shares were sold by a key executive.
• The sale represents a disposition of company stock by the CEO.

Risks

• The sale of a substantial number of shares by the CEO could be interpreted negatively by the market, potentially impacting share price.
• While executed under a 10b5-1 plan, the sheer volume of the sale might raise questions among investors about the CEO's confidence in future performance.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. The use of a 10b5-1 plan is a common strategy for executives to diversify holdings or manage personal finances without appearing to trade on material non-public information.

Stakeholder Impact

• Shareholders: May view the sale with caution, although the 10b5-1 plan provides some reassurance. The continued substantial ownership by the CEO may also be viewed positively.
• Employees: May be influenced by the CEO's stock sale, potentially impacting morale or their own investment decisions.
• Creditors: Unlikely to be directly impacted by this transaction.

Next Steps

• The reporting person may provide further details on individual sale prices upon request from the SEC, issuer, or security holders.

Key Dates

Recommendation

The filing reports a significant stock sale by the CEO under a 10b5-1 plan. While this can be a negative signal, the plan's existence and the CEO's continued substantial ownership suggest a neutral to cautious outlook. Without further financial performance data or strategic updates, a 'hold' recommendation is prudent, allowing investors to monitor future developments.

Keywords

Precigen, PGEN, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Executive Transactions, Beneficial Ownership, Stock Options